Ninlaro is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma in people who have tried at least one other therapy. Ninlaro is often combined with a corticosteroid and Revlimid to treat myeloma. Ninlaro is also known by its drug name, ixazomib.
Ninlaro is an anti-cancer drug and a member of a class of drugs called proteasome inhibitors. Ninlaro is believed to work in cases of myeloma by interfering with cell division.
How do I take it?
Ninlaro is taken orally on days 1, 8, and 15 in a 28-day cycle.
Ninlaro comes in the form of a capsule.
The FDA-approved label for Ninlaro lists common side effects including diarrhea, constipation, limb numbness and tingling, nausea, swelling, vomiting, and back pain.
Rare but serious side effects listed for Ninlaro include liver damage, fetal harm in pregnant women, skin reactions, tingling and numbness in the extremities, swelling in the limbs, and severe gastrointestinal side effects.
For more details about this treatment, visit:
Ninlaro — Takeda Oncology
Drug Therapy for Multiple Myeloma — American Cancer Society